DANAHER CORP /DE/
DHRNYSEDiagnostics & Research • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for DHR
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for DHR
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Exceed Consensus
Reported EPS of $1.94 per share for the quarter ended 2026-06-30 exceeded the same-quarter consensus estimate of $1.84 per share.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-26 was $6.27bn, up 5.54% from $5.94bn for the quarter ended 2025-06-27.
Net Income Rises Sharply
Net income for the quarter ended 2026-06-26 was $870.0m, up 56.76% from $555.0m for the quarter ended 2025-06-27.
Gross Margin Narrows
Gross margin for the quarter ended 2026-06-26 was 57.64%, narrower than the 59.35% recorded for the quarter ended 2025-06-27.
Bioprocessing Unit Misses Expectations
[2026-08-14] A financial news outlet reported that Danaher's bioprocessing unit missed expectations in Q2 2026, signaling continued softness in broader biopharma demand.
Price Chart
NYSE:DHR via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
DHRDANAHER CORP /DE/ | $216.07 | $151.9B | 30.2x | 25.4x | +4.6% | 58.5% | 3.6% |
Company Profile
About the Company
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Next Earnings Date
Oct 20, 2026
Loading latest news...